ACXP241220P1000
- 0.05
- 0.000.00%
Acurx Pharmaceuticals Newsroom
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 -- Barrons.com
Bitcoin Hits New All-Time High Above $98,000 As Spot ETFs Crack $100 Billion Net Asset Value Milestone
Acurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin Investment
Le Conseil D'administration D'Acurx Approuve Le Bitcoin En Tant Qu'actif De Réserve De Trésorerie
Acurx Pharmaceuticals Shares Are Trading Lower. The Company Announced Its Board of Directors Approved the Purchase of up to $1 Million in Bitcoin to Hold as a Treasury Reserve Asset.
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
Express News | Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural Cdi Scientific Symposium and Presented Ibezapolstat Ph2B Clinical Data Update
Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
Maxim Group Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $10
Promising Prospects for Acurx Pharmaceuticals: Buy Rating Backed by Ibezapolstat's Efficacy and Strategic Positioning
Express News | HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
Q3 2024 Acurx Pharmaceuticals Inc Earnings Call
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript Summary
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Express News | Acurx Pharmaceuticals Q3 2024 GAAP EPS $(0.17) Beats $(0.18) Estimate
Acurx Pharmaceuticals 3Q Loss $2.82M >ACXP
Acurx Pharmaceuticals 3Q Loss/Shr 17c >ACXP
Express News | Acurx Pharmaceuticals Q3 Net Income USD -2.8 Million
Express News | Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update